Welcome to Plenary Session.

This is the video and audio edition.

You're going to get audio on the usual Plenary Session feed.

You're going to get video on YouTube.

If you're listening on the Plenary Session feed, I'm doing my ASCO roundup.

I'm going to try to cover all of the papers, although I'm getting a little bit tired.

I'm going to try to cover all the papers.

If you're a fellow doing a journal club, this is going to be invaluable preparation, but I encourage you to tune into YouTube because I've got visuals, I've got

graphics, the audio just isn't the same for this session. So go to YouTube if you're listening

to the audio feed. We'll be back to pure audio sometime soon. Today we've got a big paper. We've

got Destiny Breast

4. Trasthusimab Duruxtiqan in previously treated her to low advanced breast cancer.

This is the talk of the town. I heard it got a standing ovation. People were standing up and

clapping and, well, you'll see what I have to say about it.

I think this is a hard one for me.

I spent a lot of time thinking about this paper, reading this paper.

I even had my colleague, Timothy Olivier, he read it as well.

He gave me some thoughts.

I pulled together a lot of this, and at one point you'll see how we both think the same.

Let's hit it.

All right, let's do it.

You came here for this, and I hope it doesn't disappoint.

...